

CMDBioscience, LLC

Custom designed peptides for use in the pharmaceutical, biotech & life science industries.

FOR IMMEDIATE RELEASE

CMD BIOSCIENCE AND RESEARCH FOUNDATION OF SUNY ON BEHALF OF STONY BROOK UNIVERSITY SIGN EXCLUSIVE LICENSING AGREEMENT

ORANGE, Conn., March 15, 2008 -- CMD Bioscience LLC, a privately-held bioscience company dedicated to the discovery and early-stage validation of lead peptides for use in the pharmaceutical, biotech, and diagnostic industries, signed an exclusive licensing agreement with the Research Foundation of SUNY on behalf of Stony Brook University.

The deal gives CMD Bioscience exclusive control of a computational method for predicting protein-protein and protein-peptide binding affinities. The algorithm has enormous implications for computer-aided drug design.

“We are very excited about obtaining an exclusive license for this software from the Research Foundation of SUNY on behalf of Stony Brook University,” said Dr. Joseph Audie, the CEO and founder of CMD Bioscience. “This program gives us a competitive advantage and enhances our ability to rationally design proteins and peptides for our biotech and pharmaceutical partners.”

CMD Bioscience is a Connecticut-based company that uses proprietary computational methods to solve problems of biological and therapeutic interests. Formed in 2006, the company was founded by Dr. Joseph Audie of Meriden, CT., Ph.D.

CMD Bioscience media contact:

Louis John Malafronte (203) 907-5731.

louis.malafronte@cmdbioscience.com

www.cmdbioscience.com